Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: Results from a large retrospective analysis

Clinical Genitourinary Cancer

Volumn 12, Issue 3, 2014, Pages 182-189

  De Giorgi, Ugo ^a   Scarpi, Emanuela ^a   Sacco, Cosimo ^b   Aieta, Michele ^c   Lo Re, Giovanni ^d   Sava, Teodoro ^e   Masini, Cristina ^f   De Vincenzo, Fabio ^g   Baldazzi, Valentina ^h   Camerini, Andrea ⁱ   Fornarini, Giuseppe ^j   Burattini, Luciano ^k   Rosti, Giovanni ^l   Ferrari, Vittorio ^m   Moscetti, Luca ⁿ   Chiuri, Vincenzo Emanuele ^o   Luzi Fedeli, Stefano ^p   Amadori, Dino ^a   Basso, Umberto ^q  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^c REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^d S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^e BORGO TRENTO HOSPITAL   (Italy)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^g HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^h CAREGGI UNIVERSITY HOSPITAL   (Italy)

ⁱ Versilia Hospital   (Italy)

^j UNIVERSITY OF GENOA   (Italy)

^k OSPEDALI RIUNITI   (Italy)

^l CA FONCELLO HOSPITAL   (Italy)

^m SPEDALI CIVILI   (Italy)

ⁿ BELCOLLE HOSPITAL   (Italy)

^o VITO FAZZI HOSPITAL   (Italy)

^p SAN SALVATORE HOSPITAL   (Italy)

^q VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

more..

Author keywords

Adapted regimen; Clinical outcome; First line; Older patients; Prognosis

Indexed keywords

SUNITINIB; ANGIOGENESIS INHIBITOR; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CARDIOTOXICITY; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KIDNEY METASTASIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; CARCINOMA, RENAL CELL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; KIDNEY NEOPLASMS; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SECONDARY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PYRROLES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84900336690     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2013.11.005     Document Type: Article

References (29)

1. R.J. Motzer, T.E. Hutson, and P. Tomczak et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 3584 3590
2. M. Schmidinger, J. Larkin, and A. Ravaud Experience with sunitinib in the treatment of metastatic renal cell carcinoma Ther Adv Urol 4 2012 253 265
3. V. Baldazzi, R. Tassi, and A. Lapini et al. Sunitinib-induced hyperparathyroidism: a possible mechanism to altered bone homeostasis Cancer 118 2012 3165 3172
4. J. Bellmunt, S. Négrier, and B. Escudier et al. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce Crit Rev Oncol Hematol 69 2009 64 72
5. R.J. Motzer, T.E. Hutson, and P. Tomczak et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
6. B. Escudier, T. Eisen, and W.M. Stadler et al. Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
7. C.N. Sternberg, I.D. Davis, and J. Mardiak et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
8. R. Motzer, T.E. Hutson, and D. Cella et al. Pazopanib versus sunitinib in metastatic renal cell carcinoma N Engl J Med 369 2013 722 731
9. R.J. Motzer, M. Mazumdar, and J. Bacik et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol 17 1999 2530 2540
10. D.Y. Heng, W. Xie, and M.M. Regan et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794 5799
11. J. Manola, P. Royston, and P. Elson et al. Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group Clin Cancer Res 17 2011 5443 5450
12. J.W. Coebergh, M.L. Janssen-Heijnen, and P.N. Post et al. Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of the Netherlands in 1993-1996 J Clin Epidemiol 52 1999 1131 1136
13. National Cancer Institute Common Toxicity Criteria version 3.0. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ ctcaev3.pdf. Accessed July 24, 2013.
14. D.R. Cox Regression models and life tables J R Stat Soc 34 1972 187 220
15. M. Shayne, and M.A. Lichtman Hematology in older persons M.A. Lichtman, E. Beutler, T.J. Kipps, Hematology 7th ed 2006 McGraw-Hill New York, NY 111 121
16. R.J. Motzer, T.E. Hutson, and M.R. Olsen et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma J Clin Oncol 30 2012 1371 1377
17. M.E. Gore, C. Szczylik, and C. Porta et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial Lancet Oncol 10 2009 757 763
18. T.E. Hutson, R.M. Bukowski, and B.I. Rini et al. A pooled analysis of the efficacy and safety of sunitinib in elderly patients (pts) with metastatic renal cell carcinoma (mRCC) J Clin Oncol 29 15 suppl 2011 4604
19. B.E. Houk, C.L. Bello, and D. Kang et al. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients Clin Cancer Res 15 2009 2497 2506
20. R. Khosravan, X. Huang, and R. Wiltshire et al. A retrospective analysis of data from two trials of sunitinib in patients with advanced renal cell carcinoma (RCC): pitfalls of efficacy subgroup analyses based on dose-reduction status J Clin Oncol 30 suppl 5 2012 (abstract 363)
21. D.Y. Heng, T.K. Choueiri, and J.L. Lee et al. A multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) who do not meet eligibility criteria for clinical trials J Clin Oncol 30 suppl 5 2012 (abstract 353)
22. R.A. Nelson, N. Vogelzang, and S.K. Pal A gap in disease-specific survival between younger and older adults with de novo metastatic renal cell carcinoma: results of a SEER database analysis Clin Genitourin Cancer 11 2013 303 310
23. U. Basso, S. Tonti, and C. Bassi et al. Management of frail and not-frail elderly cancer patients in a hospital-based geriatric oncology program Crit Rev Oncol Hematol 66 2008 163 170
24. M. Extermann, I. Boler, and R.R. Reich et al. Predicting the risk of chemotherapy toxicity in older patients: the chemotherapy risk assessment scale for high-age patients (CRASH) score Cancer 118 2012 3377 3386
25. U. Wedding, D. Kodding, and L. Pientka et al. Physicians' judgement and comprehensive geriatric assessment (CGA) select different patients as fit for chemotherapy Crit Rev Oncol Hematol 64 2007 1 9
26. A. Brunello, U. Basso, and C. Sacco et al. Safety and activity of sunitinib in elderly patients (≥70 years) with metastatic renal cell carcinoma: a multicenter study Ann Oncol 24 2013 336 342
27. O. Huillard, O. Mir, and M. Peyromaure et al. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients Br J Cancer 108 2013 1034 1041
28. J. Garcia-Donas, E. Esteban, and L.J. Leandro-García et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study Lancet Oncol 12 2011 1143 1150
29. E. Rossi, M. Fassan, and M. Aieta et al. Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to Sunitinib in metastatic renal cancer Br J Cancer 107 2012 1286 1294